Cholecystokinin: A multi-functional molecular switch of neuronal circuits

Developmental Neurobiology

Volumn 71, Issue 1, 2011, Pages 83-91

  Lee, Soo Yeun ^a   Soltesz, Ivan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anxiety; Cannabinoid; GABA; Interneuron; Neuropeptide

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; G PROTEIN COUPLED RECEPTOR; NEUROPEPTIDE; POTASSIUM;

ARTICLE; BEHAVIOR; CELL ACTIVITY; EPILEPSY; GABAERGIC SYSTEM; GASTROINTESTINAL TRACT; HIPPOCAMPUS; MEDICAL RECORD; MENTAL DISEASE; MOLECULAR DYNAMICS; NERVE CELL EXCITABILITY; NERVE CELL NETWORK; NEUROLOGIC DISEASE; PANIC; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNAPTIC TRANSMISSION;

ANIMALS; BRAIN; CHOLECYSTOKININ; FEAR; HUMANS; INTERNEURONS; MOLECULAR DYNAMICS SIMULATION; NERVE NET; NEURAL PATHWAYS; NEURONS;

EID: 78650047202     PISSN: 19328451     EISSN: 10974695     Source Type: Journal    
DOI: 10.1002/dneu.20815     Document Type: Article

References (81)

1. Acsady L, Kamondi A, Sik A, Freund T, Buzsaki G. 1998. GABAergic cells are the major postsynaptic targets of mossy fibers in the rat hippocampus. J Neurosci 18: 3386-3403.
2. Beinfeld MC. 2003. Biosynthesis and processing of pro CCK: Recent progress and future challenges. Life Sci 72: 747-757.
3. Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ. 1981. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 212: 51-57.
4. Bradwejn J, Koszycki D, Shriqui C. 1991. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48: 603-610.
5. Breukel AI, Lopes da Silva FH, Ghijsen WE. 1997. Cholecystokinin (CCK-8) modulates vesicular release of excitatory amino acids in rat hippocampal nerve endings. Neurosci Lett 234: 67-70.
6. Cain BM, Connolly K, Blum A, Vishnuvardhan D, Marchand JE, Beinfeld MC. 2003. Distribution and colocalization of cholecystokinin with the prohormone convertase enzymes PC1. PC2, and PC5 in rat brain. J Comp Neurol 467: 307-325.
7. Chen K, Neu A, Howard AL, Földy C, Echegoyen J, Hilgenberg L, Smith MR, et al. 2007. Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J Neurosci 27: 46-58.
8. Chen K, Ratzliff A, Hilgenberg L, Gulyas A, Freund TF, Smith M, Dinh TP, et al. 2003. Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron 39: 599-611.
9. Chhatwal JP, Gutman AR, Maguschak KA, Bowser ME, Yang Y, Davis M, Ressler KJ. 2009. Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology 34: 509-521.
10. Chung L, Moore SD. 2007. Cholecystokinin enhances GABAergic inhibitory transmission in basolateral amygdala. Neuropeptides 41: 453-463.
11. Cox CL, Huguenard JR, Prince DA. 1995. Cholecystokinin depolarizes rat thalamic reticular neurons by suppressing a K+ conductance. J Neurophysiol 74: 990-1000.
12. Cox CL, Huguenard JR, Prince DA. 1997. Peptidergic modulation of intrathalamic circuit activity in vitro: Actions of cholecystokinin. J Neurosci 17: 70-82.
13. Crawley JN. 1985. Comparative distribution of cholecystokinin and other neuropeptides. Why is this peptide different from all other peptides? Ann N Y Acad Sci 448: 1-8.
14. Daw MI, Tricoire L, Erdelyi F, Szabo G, McBain CJ. 2009. Asynchronous transmitter release from cholecystokinin-containing inhibitory interneurons is widespread and target-cell independent. J Neurosci 29: 11112-11122.
15. de Montigny C. 1989. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry 46: 511-517.
16. Deng PY, Lei S. 2006. Bidirectional modulation of GABAergic transmission by cholecystokinin in hippocampal dentate gyrus granule cells of juvenile rats. J Physiol 572: 425-442.
17. Deng PY, Xiao Z, Jha A, Ramonet D, Matsui T, Leitges M, Shin HS, et al. 2010. Cholecystokinin facilitates glutamate release by increasing the number of readily releasable vesicles and releasing probability. J Neurosci 30: 5136-5148.
18. Deschenes RJ, Lorenz LJ, Haun RS, Roos BA, Collier KJ, Dixon JE. 1984. Cloning and sequence analysis of a cDNA encoding rat preprocholecystokinin. Proc Natl Acad Sci USA 81: 726-730.
19. Dockray GJ. 1980. Cholecystokinins in rat cerebral cortex: Identification, purification and characterization by immunochemical methods. Brain Res 188: 155-165.
20. Dodd PR, Edwardson JA, Dockray GJ. 1980. The depolarization-induced release of cholecystokinin C-terminal octapeptide (CCK-8) from rat synaptosomes and brain slices. Regul Pept 1: 17-29.
21. Emson PC, Lee CM, Rehfeld JF. 1980. Cholecystokinin octapeptide: Vesicular localization and calcium dependent release from rat brain in vitro. Life Sci 26: 2157-2163.
22. Ferrier IN, Roberts GW, Crow TJ, Johnstone EC, Owens DG, Lee YC, O'Shaughnessy D, et al. 1983. Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci 33: 475-482.
23. Földy C, Lee SY, Szabadics J, Neu A, Soltesz I. 2007. Cell type-specific gating of perisomatic inhibition by cholecystokinin. Nat Neurosci 10: 1128-1130.
24. Freund TF. 2003. Interneuron diversity series: Rhythm and mood in perisomatic inhibition. Trends Neurosci 26: 489-495.
25. Freund TF, Katona I. 2007. Perisomatic inhibition. Neuron 56: 33-42.
26. Gallopin T, Geoffroy H, Rossier J, Lambolez B. 2006. Cortical sources of CRF. NKB, and CCK and their effects on pyramidal cells in the neocortex. Cereb Cortex 16: 1440-1452.
27. Ghijsen WE, Leenders AG, Wiegant VM. 2001. Regulation of cholecystokinin release from central nerve terminals. Peptides 22: 1213-1221.
28. Glickfeld LL, Scanziani M. 2006. Distinct timing in the activity of cannabinoid-sensitive and cannabinoid-insensitive basket cells. Nat Neurosci 9: 807-815.
29. Harro J. 2006. CCK and NPY as anti-anxiety treatment targets: Promises, pitfalls, and strategies. Amino Acids 31: 215-230.
30. Hart SA, Snyder MA, Smejkalova T, Woolley CS. 2007. Estrogen mobilizes a subset of estrogen receptor-alpha-immunoreactive vesicles in inhibitory presynaptic boutons in hippocampal CA1. J Neurosci 27: 2102-2111.
31. Hefft S, Jonas P. 2005. Asynchronous GABA release generates long-lasting inhibition at a hippocampal interneuron-principal neuron synapse. Nat Neurosci 8: 1319-1328.
32. Hendry SH, Jones EG, Beinfeld MC. 1983. Cholecystokinin-immunoreactive neurons in rat and monkey cerebral cortex make symmetric synapses and have intimate associations with blood vessels. Proc Natl Acad Sci USA 80: 2400-2404.
33. Hilke S, Hokfelt T, Darwish M, Theodorsson E. 2007. Cholecystokinin levels in the rat brain during the estrous cycle. Brain Res 1144: 70-73.
34. Hill DR, Campbell NJ, Shaw TM, Woodruff GN. 1987. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 7: 2967-2976.
35. Hokfelt T, Rehfeld JF, Skirboll L, Ivemark B, Goldstein M, Markey K. 1980. Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature 285: 476-478.
36. Honda T, Wada E, Battey JF, Wank SA. 1993. Differential gene expression of CCK(A) and CCK(B) receptors in the rat brain. Mol Cell Neurosci 4: 143-154.
37. Innis RB, Snyder SH. 1980. Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 77: 6917-6921.
38. Karson MA, Tang AH, Milner TA, Alger BE. 2009. Synaptic cross talk between perisomatic-targeting interneuron classes expressing cholecystokinin and parvalbumin in hippocampus. J Neurosci 29: 4140-4154.
39. Karson MA, Whittington KC, Alger BE. 2008. Cholecystokinin inhibits endocannabinoid-sensitive hippocampal IPSPs and stimulates others. Neuropharmacology 54: 117-128.
40. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF. 1999. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544-4558.
41. Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J, Fourie O. 1999. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4: 284-285.
42. Kerwin R, Robinson P, Stephenson J. 1992. Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: A post-mortem autoradiographic study. Psychol Med 22: 37-43.
43. Klausberger T. 2009. GABAergic interneurons targeting dendrites of pyramidal cells in the CA1 area of the hippocampus. Eur J Neurosci 30: 947-957.
44. Klausberger T, Marton LF, O'Neill J, Huck JH, Dalezios Y, Fuentealba P, Suen WY, et al. 2005. Complementary roles of cholecystokinin- and parvalbumin-expressing GABAergic neurons in hippocampal network oscillations. J Neurosci 25: 9782-9793.
45. Kosaka T, Kosaka K, Tateishi K, Hamaoka Y, Yanaihara N, Wu JY, Hama K. 1985. GABAergic neurons containing CCK-8-like and/or VIP-like immunoreactivities in the rat hippocampus and dentate gyrus. J Comp Neurol 239: 420-430.
46. Kurrikoff K, Inno J, Matsui T, Vasar E. 2008. Stress-induced analgesia in mice: Evidence for interaction between endocannabinoids and cholecystokinin. Eur J Neurosci 27: 2147-2155.
47. Lee SH, Földy C, Soltesz I. 2010. Distinct endocannabinoid control of GABA release at perisomatic and dendritic synapses in the hippocampus. J Neurosci 30: 7993-8000.
48. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, et al. 2002. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
49. Meis S, Munsch T, Sosulina L, Pape HC. 2007. Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to cholecystokinin are mediated by a transient receptor potential-like current. Mol Cell Neurosci 35: 356-367.
50. Micevych P, Sinchak K. 2001. Estrogen and endogenous opioids regulate CCK in reproductive circuits. Peptides 22: 1235-1244.
51. Migaud M, Durieux C, Viereck J, Soroca-Lucas E, Fournie-Zaluski MC, Roques BP. 1996. The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 17: 601-607.
52. Migaud M, Roques BP, Durieux C. 1994. Effects of cholecystokinin octapeptide and BC 264, a potent and selective CCK-B agonist on aspartate and glutamate release from rat hippocampal slices. Neuropharmacology 33: 737-743.
53. Migaud M, Roques BP, Durieux C. 1995. Evidence for a high-affinity uptake system for cholecystokinin octapeptide (CCK8) in rat cortical synaptosomes. Eur J Neurosci 7: 1074-1079.
54. Miller KK, Hoffer A, Svoboda KR, Lupica CR. 1997. Cholecystokinin increases GABA release by inhibiting a resting K+ conductance in hippocampal interneurons. J Neurosci 17: 4994-5003.
55. Noble F, Roques B. 2006. Cholecystokinin peptides in brain function. In: Lajtha A, Lim R, editors. Handbook of Neurochemistry and Molecular Neurobiology. New York: Springer US, pp 545-571.
56. Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, Roques BP. 1999. International union of pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 51: 745-781.
57. Nunzi MG, Gorio A, Milan F, Freund TF, Somogyi P, Smith AD. 1985. Cholecystokinin-immunoreactive cells form symmetrical synaptic contacts with pyramidal and nonpyramidal neurons in the hippocampus. J Comp Neurol 237: 485-505.
58. Nyiri G, Cserep C, Szabadits E, Mackie K, Freund TF. 2005. CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136: 811-822.
59. Oz M, Yang KH, Shippenberg TS, Renaud LP, O'Donovan MJ. 2007. Cholecystokinin B-type receptors mediate a G-protein-dependent depolarizing action of sulphated cholecystokinin ocatapeptide (CCK-8s) on rodent neonatal spinal ventral horn neurons. J Neurophysiol 98: 1108-1114.
60. Pommier B, Da Nascimento S, Dumont S, Bellier B, Million E, Garbay C, Roques BP, et al. 1999. The cholecystokininB receptor is coupled to two effector pathways through pertussis toxin-sensitive and -insensitive G proteins. J Neurochem 73: 281-288.
61. Pommier B, Marie-Claire C, Da Nascimento S, Wang HL, Roques BP, Noble F. 2003. Further evidence that the CCK2 receptor is coupled to two transduction pathways using site-directed mutagenesis. J Neurochem 85: 454-461.
62. Roques BP. 2000. Novel approaches to targeting neuropeptide systems. Trends Pharmacol Sci 21: 475-483.
63. Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB, Bishop PB, Chan SM, et al. 1996. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature 380: 403-409.
64. Saito A, Sankaran H, Goldfine ID, Williams JA. 1980. Cholecystokinin receptors in the brain: Characterization and distribution. Science 208: 1155-1156.
65. Sanjuan J, Toirac I, Gonzalez JC, Leal C, Molto MD, Najera C, De Frutos R. 2004. A possible association between the CCK-AR gene and persistent auditory hallucinations in schizophrenia. Eur Psychiatry 19: 349-353.
66. Sankaran H, Goldfine ID, Deveney CW, Wong KY, Williams JA. 1980. Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini. J Biol Chem 255: 1849-1853.
67. Sayin U, Osting S, Hagen J, Rutecki P, Sutula T. 2003. Spontaneous seizures and loss of axo-axonic and axo-somatic inhibition induced by repeated brief seizures in kindled rats. J Neurosci 23: 2759-2768.
68. Soltesz I. 2006. Diversity in the Neuronal Machine: Order and Variability in Interneuronal Microcircuits. New York: Oxford University Press.
69. Somogyi P, Hodgson AJ, Smith AD, Nunzi MG, Gorio A, Wu JY. 1984. Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin-immunoreactive material. J Neurosci 4: 2590-2603.
70. Tirassa P, Costa N, Aloe L. 2005. CCK-8 prevents the development of kindling and regulates the GABA and NPY expression in the hippocampus of pentylenetetrazole (PTZ)-treated adult rats. Neuropharmacology 48: 732-742.
71. Toledo-Rodriguez M, Goodman P, Illic M, Wu C, Markram H. 2005. Neuropeptide and calcium-binding protein gene expression profiles predict neuronal anatomical type in the juvenile rat. J Physiol 567: 401-413.
72. Tsujino N, Yamanaka A, Ichiki K, Muraki Y, Kilduff TS, Yagami K, Takahashi S, et al. 2005. Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. J Neurosci 25: 7459-7469.
73. van der Kooy D, Hunt SP, Steinbusch HW, Verhofstad AA. 1981. Separate populations of cholecystokinin and 5-hydroxytryptamine-containing neuronal cells in the rat dorsal raphe, and their contribution to the ascending raphe projections. Neurosci Lett 26: 25-30.
74. Van Dijk A, Richards JG, Trzeciak A, Gillessen D, Mohler H. 1984. Cholecystokinin receptors: biochemical demonstration and autoradiographical localization in rat brain and pancreas using [3H] cholecystokinin8 as radioligand. J Neurosci 4: 1021-1033.
75. Vanderhaeghen JJ, Signeau JC, Gepts W. 1975. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 257: 604-605.
76. Verhage M, Ghijsen WE, Nicholls DG, Wiegant VM. 1991a. Characterization of the release of cholecystokinin-8 from isolated nerve terminals and comparison with exocytosis of classical transmitters. J Neurochem 56: 1394-1400.
77. Verhage M, McMahon HT, Ghijsen WE, Boomsma F, Scholten G, Wiegant VM, Nicholls DG. 1991b. Differential release of amino acids, neuropeptides, and catecholamines from isolated nerve terminals. Neuron 6: 517-524.
78. Wank SA. 1995. Cholecystokinin receptors. Am J Physiol 269: G628-G646.
79. Wei J, Hemmings GP. 1999. The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia. Eur Psychiatry 14: 67-70.
80. You ZB, Herrera-Marschitz M, Brodin E, Meana JJ, Morino P, Hokfelt T, Silveira R, et al. 1994. On the origin of striatal cholecystokinin release: Studies with in vivo microdialysis. J Neurochem 62: 76-85.
81. Zhu PC, Thureson-Klein A, Klein RL. 1986. Exocytosis from large dense cored vesicles outside the active synaptic zones of terminals within the trigeminal subnucleus caudalis: A possible mechanism for neuropeptide release. Neuroscience 19: 43-54.